Pre-made Fianlimab benchmark antibody ( Whole mAb, anti-LAG3 therapeutic antibody, Anti-CD223 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-210

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-210 Category Tag

Product Details

Pre-Made Fianlimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Fianlimab (previously REGN 3767) is an anti-lymphocyte-activation gene 3 (LAG3) monoclonal antibody, being developed by Regeneron Pharmaceuticals, for the treatment of solid tumours and haematological malignancies.

Products Name (INN Index)

Pre-Made Fianlimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody

INN Name

Fianlimab

Target

LAG3

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2019

Companies

Regeneron Pharmaceuticals

Conditions Approved

NA

Conditions Active

Cancer

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

LAG3

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide